MentalHealthDaily

Alzheimer’s Disease, Microglia, & Environmental Risk Factors (2024 Evidence)

by GLOOM

Alzheimer’s disease, a debilitating neurodegenerative condition, is influenced significantly by a blend of genetic, environmental, and lifestyle factors. New research focuses on environmental risk factors and microglia (the brain’s immune cells) for Alzheimer’s development. Highlights: Alzheimer’s Disease and Microglia: Alzheimer’s is characterized by cognitive decline, and microglia play a crucial role in its pathogenesis, acting …

Caffeine’s Effects on Cerebral Blood Flow (CBF): What You Should Know

by GLOOM

Caffeine, a ubiquitous stimulant, is known for its ability to enhance alertness and cognitive function. But beyond these surface-level effects lies a complex interaction with the body’s cardiovascular and neurological systems, particularly influencing cerebral blood flow. Highlights: Global Ubiquity: Caffeine is the most widely consumed pharmacologically active substance worldwide. Dose-Dependent Effects: Caffeine’s influence on cerebral …

Cognitive Enhancement Effects of Caffeine, Methylphenidate, Modafinil (Study)

by GLOOM

In the pursuit of peak mental performance, scientific studies have explored the effects of stimulants like methylphenidate, modafinil, and caffeine on cognitive functions such as memory and attention. Recent research utilizing advanced neuroimaging techniques has begun to unravel the intricate ways these substances modulate brain activity and connectivity, offering insights into their potential as cognitive …

Microplastics & Nanoplastics Cross Blood-Brain Barrier within Hours & May Cause Damage

by GLOOM

Microplastics and nanoplastics (MNPs) from the breakdown of plastic materials pollute the environment and make their way into the human body, raising concerns over potential health impacts. Research shows that microplastics and nanoplastics are able to cross the blood-brain barrier in mice within 2 hours of ingestion. Key Facts: Polystyrene nanoparticles with a size of …

Semaglutide & Empagliflozin May Treat Obesity-Related Cognitive Impairment (Mouse Study)

by GLOOM

Obesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between obesity, reduced brain volume and neuronal loss, increased dementia risk, and impaired learning, memory and cognition. Preliminary evidence suggests that weight loss drugs like semaglutide may …

New Epilepsy Treatments (2023): Neurostimulation, CBD, Gene Therapy for Seizures

by GLOOM

Epilepsy affects over 50 million people worldwide, making it one of the most common neurological disorders globally. For many living with epilepsy, achieving reliable seizure control remains a significant challenge, underscoring the need for continued innovation in treatment approaches. Exciting new developments in the field are providing clinicians with an expanding array of therapeutic options …

Depressed vs. Anxious Brains: Differences in Brain Waves & Connectivity Revealed

by GLOOM

Advanced analysis of multidimensional EEG data reveals significant differences in brain activity patterns between Generalized Anxiety Disorder (GAD) and Depressive Disorder (DD). The distinguishing factors seem to be differences in beta brain waves and functional connectivity between various brain regions. Key Facts: Patients with DD exhibited higher power spectrum density (PSD) values and fuzzy entropy …